Literature DB >> 12424859

Site-dependent resection techniques for gastric cancer.

Hubert J Stein1, Andreas Sendler, Jörg R Siewert.   

Abstract

In addition to tumor stage and growth pattern, the tumor site is a major factor in determining the extent of resection and lymphadenectomy necessary in patients with gastric carcinoma. Total gastrectomy with D2-lymphadenectomy is the procedure of choice for tumors of the gastric corpus. Extended total gastrectomy with trans-hiatal resection of the distal esophagus is required for tumors of the proximal region; in these patients lymphadenectomy may also include splenic hilum and left retroperitoneal nodes. In patients with distal gastric carcinoma, a subtotal gastrectomy often achieves a complete tumor resection. Extended lymphadenectomy in these patients includes the retroduodenal and right para-aortic nodes in addition to a D2-dissection. In patients with early tumor stages, anatomically oriented limited resection techniques are increasingly important. The concept of the sentinel lymph node may result in more selective lymphadenectomy strategies in the near future [15]. For patients with a locally advanced disease, these surgical concepts must be evaluated within multimodal treatment protocols [16].

Entities:  

Mesh:

Year:  2002        PMID: 12424859     DOI: 10.1016/s1055-3207(02)00017-0

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  13 in total

Review 1.  Current status and future clinical applications of lymphatic mapping in gastrointestinal cancer.

Authors:  Yuko Kitagawa; Sukamal Saha
Journal:  J Gastroenterol       Date:  2007-12-25       Impact factor: 7.527

2.  Length of negative resection margin does not affect local recurrence and survival in the patients with gastric cancer.

Authors:  Chang Min Lee; Ye Seob Jee; Ju-Hee Lee; Sang-Yong Son; Sang-Hoon Ahn; Do Joong Park; Hyung-Ho Kim
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

3.  Laparoscopy-assisted distal gastrectomy versus laparoscopy-assisted total gastrectomy with D2 lymph node dissection for middle-third advanced gastric cancer.

Authors:  Zhengyan Li; Gang Ji; Bin Bai; Deliang Yu; Yezhou Liu; Bo Lian; Qingchuan Zhao
Journal:  Surg Endosc       Date:  2017-11-02       Impact factor: 4.584

4.  [Anastomotic leaks in the upper gastrointestinal tract].

Authors:  J R Siewert; H J Stein; H Bartels
Journal:  Chirurg       Date:  2004-11       Impact factor: 0.955

5.  Clinicopathological features of patients with middle third gastric carcinoma.

Authors:  Jin Hong Kim; Jae Kyoon Joo; Seong Yeob Ryu; Ho Gun Kim; Jae Hyuk Lee; Dong Yi Kim
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

6.  Clinicopathologic characteristics and outcomes of surgery of middle-third gastric cancer.

Authors:  Jingyu Deng; Han Liang; Rupeng Zhang; Dan Sun; Yi Pan; Li Zhang; Xishan Hao
Journal:  Tumour Biol       Date:  2012-08-07

7.  Which Is the Optimal Extent of Resection in Middle Third Gastric Cancer between Total Gastrectomy and Subtotal Gastrectomy?

Authors:  Ji Hyun Lee; Yong Il Kim
Journal:  J Gastric Cancer       Date:  2010-12-31       Impact factor: 3.720

8.  Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer.

Authors:  Zi-Yu Li; Fei Shan; Lian-Hai Zhang; Zhao-De Bu; Ai-Wen Wu; Xiao-Jiang Wu; Xiang-Long Zong; Qi Wu; Hui Ren; Jia-Fu Ji
Journal:  World J Surg Oncol       Date:  2011-09-26       Impact factor: 2.754

9.  The distance of proximal resection margin dose not significantly influence on the prognosis of gastric cancer patients after curative resection.

Authors:  Min Gyu Kim; Ju-Hee Lee; Tae Kyung Ha; Sung Joon Kwon
Journal:  Ann Surg Treat Res       Date:  2014-10-24       Impact factor: 1.859

10.  Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.

Authors:  Stuart G Marcus; Daniel Cohen; Ke Lin; Kwok Wong; Scott Thompson; Adina Rothberger; Milan Potmesil; Spiros Hiotis; Elliot Newman
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.